Cat. No.: DAB-0012697
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP, IF |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the human sequence of PI4 Kinase. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PI4KA |
| UniProt No. | P42356 |
| Gene ID | 5297 |
| Gene Description | Inositol phospholipids have an important role in intracellular signaling in response to hormones, growth factors and neurotransmitters. Phosphatidylinositol 4-kinase phosphorylates phosphatidylinositol to phosphatidylinositol-4-phosphate. In a second step, PIP is further phosphorylated to phosphatidylinositol-4, 5-bisphosphate, and PIP2 is subsequently hydrolyzed by phospholipase C, producing the two intracellular second messengers, inositol 1, 4, 5-triphosphate and diacylglycerol. PI4K230, PI4K92 and PI4K55 are three PI4 kinase isoforms that have been characterized and classified according to their molecular weights of 230, 92 and 55 kD. Previously, PI4 kinases were classified into type II and III enzymes. All isoforms are located on distinct membranes and cellular compartments suggesting various tasks. PI4K230 is located at the endoplasmatic reticulum and outer membranes of mitochondria, PI4K92 at the Golgi apparatus and endoplasmatic reticulum, and PI4K55 at the plasma membrane and endosomes. PI4K230 is predominantly expressed in brain and moderately sensitive to wortmannin as well as specifically and irreversibly inhibited by cyclitol derivatives. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
